Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Beaufort Securities' Rating of N4 Pharma on 2/5/2018

On February 5, 2018, Beaufort Securities updated its outlook on N4 Pharma (LON:N4P) with the action "Reiterated Rating", keeping a "Speculative Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.